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ABSTRACT 
Research objective. To determine the relationship between allelic variants of the 
polymorphic marker of PAI-1 gene with the risk factors of ischemic heart disease (IHD) in 
Uzbek nationality. 
Material and methods. 126 respondents were examined: 61 patients with stable angina 
(SA) aged 45 to 60 years (males) who were hospitalized in the cardiology department of the 1st 
TMA clinic in Tashkent. In the comparison group were 65 unrelated males of Uzbek nationality 
without clinical signs of coronary artery disease. The examined noted: arterial hypertension (AH) 
in 53 people, hypercholesterolemia (HCH) in 38 people, obesity in 23 people, smoking in 22 
people. 
The diagnosis –SA was verificated in compliance with classification of IHD accepted at the 
IV congress of cardiologists (2000) became criteria of including of patients. Functional class of 
SA was established on the basis of classification of stable angina of the Canadian society of 
cardiologists (1976) and exciting test veloergometry. 
Criteria of an exception of a research- patients with unstable angina, myocardial infarction 
(MI), an acute and chronic heart, renal, liver failure, patients with an arrhythmia, acute disorders 
of a cerebral circulation, the diabetes mellitus, malignant neoplasms. 
Results. The analysis of genotyping of the studied persons of the Uzbek nationality 
showed that, in patients with IHD mutagen allele 4G of gene PAI-1 in homozygous (4G/4G) and 
heterozygous (4G/5G) state what makes 21,3% and 47,5%, respectively, meets more than in 
group of healthy faces at which given distributions of genotypes made 9,2% and 38,5%. Points 
these data probability of influence of existence of 4G allele of PAI-1 gene, especially in a 
heterozygous state, to development of IHD. 
5G/5G the group of healthy faces in number of 34 people in 52.3% of cases, than at 19 
(31,1%) IHD patients caused a stir in the greatest occurrence of a favorable genotype. Thus, 
these differences have the high statistical importance and wear, nonrandom character (р<0.05). 
Conclusion. The genotyping of the coagulation factor PAI-1 in the examined patients 
revealed the presence of unfavorable genotypes 4G/4G and 4G/5G was established more often in 
patients with coronary artery disease in 21.3% and 47.5% of cases, respectively, compared with 
the group of healthy individuals who This distribution of genotypes was 9.2% and 38.5%. 
Whereas, the prevalence rate of the 5G/5G genotype was prevalent in 52.3% of the control group 
over the spread of 31.1% of patients in the IHD. 
Key words: Ischemic heart disease, genetic polymorphism, plasminogen activator 
inhibitor, 4G/5G, risk factors. 
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INTRODUCTION 
Genetic variations of the serine proteinase inhibitor family E member 1 (SERPINE1) 
gene, which encodes plasminogen activator inhibitor 1, correlate with serum levels of its product 
and are associated with thrombophilia and coronary atherosclerosis. Various SERPINE1 ;gene 
polymorphisms have been identified. However, only the functional 5G/4G polymorphism has 
been assessed in the context of aneurysmal subarachnoid hemorrhage (aSAH). We assessed 
associations of 6 SERPINE1 polymorphisms with the clinical sequelae of aSAH. SERPINE1 
gene polymorphisms were associated with delayed cerebral ischemia and functional outcome 
after aSAH. These associations may arise from alterations of plasminogen activator inhibitor 1 
levels [1]. 
The risk of thrombotic events can also be affected by variations in Plasminogen 
Activator Inhibitor type 1 activity (PAI-1) [2]. This molecule belongs to the serpin family 
inhibitors and is one of the key inhibitors of plasmin generation in the plasma and tissues. It acts 
by inhibiting the activity of the fibrinolytic system, via inhibition of tPA (tissue plasminogen 
activator) and uPA (urokinase plasminogen activator). Localized on the chromosome 7, PAI-1 
gene covers 16 Kb of longer and contains9 exons. It encodes for a protein of 50 KDa, composed 
by 379 amino acids [3]. A single insertion/deletion of a “G” at position − 675 in the promoter 
region of the gene gives rise to 4G and 5G alleles, which differ by their regulation of PAI-1 
activity[4]. Numerous studies have found an association between SNPs in PAI-1 gene and the 
development of many diseases (HTA, stroke…); concerning (MI), results remain contradictory 
[5].  
Plasminogen activator inhibitor-1 (PAI-1) is a protein of interest for both arterial 
remodeling and thrombotic risk as it regulates cell migration and vascular thrombosis. Elevated 
PAI-1 antigen levels have been identified as a potential biomarker for coronary artery disease 
and metabolic syndrome while being modulated by a number of atherosclerotic risk factors. 
Although linked by some studies as a marker of disease severity and prognosis, it remains to be 
understood whether it is also a mediator and/or therapeutic target of vascular disease. In this 
review, we discuss the current understanding of PAI-1 in vascular disease and its potential role 
in in-stent restenosis and stent thrombosis [6] 
PAI-1 gene polymorphisms could change its generation level. Moreover it has been linked 
to worsening of some thrombotic diseases; as coronary heart disease, atherosclerosis and stroke 
[7]. Investigated the effects of overweight/obesity and lifestyle (smoking and alcohol intake) on 
plasma PAI-1 levels in 203 healthy men (age 44.5 ± 8.1) who visited our department for health 
check. These results suggest that overweight/obesity and unfavorable lifestyle such as smoking 
and heavy alcohol consumption may increase plasma PAI-1 levels and might be linked to the 
risk of ischemic heart disease [8]. 
High plasma PAI-1 levels have been shown to be associated 
with atherosclerosis, restenosis, and in the pathogenesis of disorders associated with thrombotic 
events such as myocardial infarction and deep venous thrombosis [9,10,11]. 
It was reported that PAI-1 gene polymorphism such as 4G/5G and 4G/4G genotypes has 
been associated with the higher gene expression and higher PAI-1 levels in the circulation 
resulting in an increased risk for thrombotic events such as MI and stroke [12,13,14,15,16] 
It has been proven that there are synergistic and cumulative effects of the 5G allele of PAI-
1 polymorphism and the C allele of IL-6 polymorphism in smoking when determining the risk 
associated with coronary heart disease [17]. In a study by Hoekstra et al., 2002, the relationship 
of 4G / 5G polymorphism with intima media carotid artery parameters was studied in young 
smokers. [18].  
The effect of RAS polymorphisms on t-PA and PAI-1 levels has been studied previously, 
but no data are available about the joint effects of RAS and bradykinin gene polymorphisms on 
markers of the fibrinolytic system [19]. The I/D polymorphism of the ACE gene has been 
associated with PAI-1 levels in apparently healthy persons 
https://www.sciencedirect.com/science/article/pii/S0888754306003223 - bib13, in patients with 
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hypertension [20], and in patients attending a metabolic ward [21] 
https://www.sciencedirect.com/science/article/pii/S0888754306003223 - bib14.  
According to the literature, the relationship between PAI-1 and tPA levels with stroke was 
investigated (function of the PAI-1 4G / 5G and -844G / A genotypes), as well as the relationship 
between these PAI-1 gene variants and stroke risk in a control study of 135 patients with 
ischemic stroke.  Regression analysis demonstrated that 4G homozygosity (OR = 0.176), 
hypertension (OR = 6.288), and body mass index (OR = 1.325) were independent predictors of 
stroke. The protective effect of 4G allele against stroke suggests involvement of PAI-1 4G/5G 
polymorphism in stroke through a mechanism not related to fibrinolysis, possibly involving 
altered plaque stabilization, and/or through antagonism of tPA effects [22]. 
The fact that, essential hypertension predisposes to the procoagulant state characterized by 
hyperfibrinogenemia and hypofibrinolysis. Perindopril reduced fibrinogen levels in ACE II 
homozygotes due to its more potent inhibitory action on the renin-angiotensin system in such 
patients. It improved fibrinolysis by increasing t-PA levels regardless of ACE and PAI-1 
genotype [23]. 
In one study, the effect of gene interaction on the MI risk gene was analyzed, combinations 
of G894T eNOS-4G / 5G PAI, G894T eNOS-T1131C APOA5 and 4G / 5G PAI-T1131C 
APOA5 were studied, and the dependence or absence of their only effect on the risk of heart 
attack was evaluated myocardium. Results suggest that the eNOS and APOA5 genes might be 
dependently associated with MI' risk of occurrence, as the P values of the associated genotype-
combinations were lower than those obtained by the analysis of each gene separately. The 
associations of PAI gene with eNOS and APOA5 were statistically very significant; however, 
the P values of the associated genotypic-combinations were identical or superior to those 
obtained by the simple analysis of each one of them, indicating that their actions on MI risk are 
likely to be independent [24]. 
 High PAI-1 levels after acute myocardial infarction (AMI) are associated with poor 
outcomes. The concentrations of insulin-like molecules, pro-inflammatory cytokines and 
insertion polymorphism (5G) / deletion (4G) in the promoter of the PAI-1 gene affect the level of 
circulating PAI-1. No evidence was found that subjects with 4G / 4G polymorphism had higher 
PAI-1 levels upon admission or 6 months after AMI. In these patients, PAI-1 levels are 
associated with concentrations of proinsulin-like molecules and pro-inflammatory cytokines 
[25]. 
 To investigate whether the 4G/5G polymorphism of plasminogen activator inhibitor type 1 
(PAI-1) and the −7351 C/T polymorphism of tissue-type plasminogen activator (t-PA) are 
associated with ischemic stroke, was conducted a case-control study of 190 hospital cases of 
first-ever ischemic stroke and 185 community-based controls. Findings do not indicate any 
association between the PAI-1 or t-PA polymorphisms and risk of stroke. Adding these results to 
previous studies in a meta-analysis indicated a strong association between this polymorphism 
and ischemic stroke (P = .0002), with no publication bias but with extreme heterogeneity. There 
was evidence of stroke association with the PAI-1 4G/5G locus [25]. 
From the analysis of published data, various relationships of the PAI-1 gene with the main 
symptoms of cardiovascular diseases and their risk factors are traced. For example, the 4G/5G 
genotypes and plasma PAI-1 levels were determined in 565 Chinese, 211 with and 354 without 
hypertension to study the genotype effect and the mode of gene–environment interaction. The 
present study showed that the 4G/4G genotype was associated with elevated plasma PAI-1 
activity in Chinese patients with and without hypertension. The contribution of the PAI-1 
genotype seemed larger in women. In hypertensive carrying the 4G/4G genotype, higher TG was 
correlated with higher PAI-1, suggesting a possible contribution of gene–environmental 
interaction to their high risk for atherothrombotic disease [26]. 
Аlso discovered сlock and Bmal1 genes polymorphisms were independent risk factors of 
elevated plasm PAI-1 in hypertensive patients (the innovation fund project of Fujian Province 
Health Department) [27] 
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Prolonged euglobulin clot lysis time (ECLT) and increased level of plasminogen activator 
inhibitor-1 (PAI-1) were reported to be risk factors of arterial ischemic stroke (AIS) by some 
studies; however, these findings were not supported by other studies. The objective of this study 
was to determine the association of ECLT, PAI-1 level, and polymorphisms of 4G and 5G of 
PAI-1 gene to the development of ischemic stroke (IS) in Thai children. However, these results 
have not been confirmed by other studies. For example, in children from 1 to 18 years old in 
Thailand, the relationship of ECLT, the level of PAI-1 and the 4G and 5G polymorphisms of the 
PAI-1 gene with the development of ischemic stroke (II) was investigated. The PAI-1 level and 
4G/5G polymorphism may not be a risk factor of AIS in this population. But it was found that 
4G / 5G polymorphism was the most common PAI-1 genotype in this study [28]. 
In a study conducted by Tunisians to detect a link between PAI-1 and myocardial 
infarction (MI) gene polymorphism, MI was accelerated by acquired and hereditary risk factors, 
including G/A and 4G/5G polymorphisms in the plasminogen activator inhibitor inhibitor gene 
promoter -1 (PAI-1). This study indicates that the risk of MI was notably high in 4G carriers and 
a carriers with elevated plasma PAI-1, and were associated with reduced t-PA levels [29]. 
Currently, it is possible to predict the development of coronary heart disease (CHD) as a 
result of revealing a genetic predisposition to dyslipidemia with the development of vascular 
atherosclerosis, to a disturbance of the blood coagulation system and fibrinolysis, to endothelial 
dysfunction and remodeling of the vascular wall, hypertrophy and remodeling of the left 
ventricle myocardium. To the category of actively studied genetic factors, certain allelic variants 
of which may be associated with an increased risk of exacerbation of IHD, include polymorphic 
markers of genes encoding substances - regulators of vascular tone, hemostasis and lipid 
metabolism, in particular, endothelin-1 gene, endothelial nitric oxide synthetase 3 type, ACE 
inhibitor, fibrinogen, platelet glycoprotein receptors, lipoprotein lipase and others, since the level 
of these biologically active substances is an independent developmental RF cardio-vascular 
complications [30]. 
In some cases, a patient under 40-50 years old is expected to have a high risk of developing 
(MI), and the likelihood of developing this form of IHD with certain allelic variants of the genes 
increases sharply. It should be noted that a relatively small number of prospective studies allows 
us to establish the real prognostic value of candidate genes in comparison with the prognostic 
value of other factors of cardiovascular risk. 
An elevated level of plasminogen activator inhibitor type I (PAI-1) is associated with a 
more severe course of IHD. The mechanism of this increase is still not clear. One possible 
hypothesis to explain this condition is its genetic predisposition. It is known that the level of 
mRNA transcription of the PAI-1 gene correlates with a specific allelic variant of this gene. This 
is what allows us to consider the PAI-1 gene as one of the possible candidate genes that 
determine the hereditary predisposition to IHD [31]. Most often, a mononucleotide polymorphic 
deletion / insertion marker located in the promoter region at position - 675 (4G (-675) 5G) is 
used in studies. Carriers of the 4G allele, both in the hetero- and homozygous state, have a higher 
level of plasma PAI-1 and a greater risk of developing acute coronary syndromes [32]. 
In continuing research in this direction, we studied the prevalence of a type I plasminogen 
activator inhibitor (PAI-1) among respondents of Uzbek nationality. 
 
MATERIALS AND RESEARCH METHODS 
126 respondents were examined: 61 patients with coronary heart disease (CHD) aged 45 to 
60 years (males) who were hospitalized in the cardiology department of the 1st TMA clinic in 
Tashkent. In the comparison group were 65 unrelated males of Uzbek nationality without clinical 
signs of coronary artery disease. The examined noted: AH in 53 people, GHS in 38 people, 
obesity in 23 people, smoking in 22 people. 
The average age in both groups was: 56.8 ± 6.40 years (42 to 66 years). Respondents 
included in the study suffered from ischemic heart disease of 11.4 ± 2.47 years. Analysis of 
DNA samples by the PAI-I gene (4G / 5G) was carried out by multiplex and standard 
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polymerase chain reaction and on thermal cyclers СG-1-96 “CorbettResearch” (Australia) and 
2720 “AppliedBiosystems” (USA), using kits of LLC “GenoTehnologiya” ”and“ Litekh 
”(Moscow), according to the manufacturers instructions. The SNP-express system is a set of 
reagents for detecting mutations (polymorphisms) in the human genome. 
Two amplification reactions are conducted in parallel with a sample of isolated DNA, with 
two pairs of allele-specific primers. The results of the analysis allow us to give three types of 
conclusions: homozygote for allele 1; heterozygous; homozygote for the allele 2. 
Mathematical Analysis of the Methods 
The deviation of the distribution of genotypes from the canonical distribution of Hardy-
Weinberg was estimated using the computer program “GenePop”. Predictive efficiency (AUC-
classifier) was determined by the standard formula: AUC = (Se + Sp) / 2; where Se and Sp are 
the sensitivity and specificity of the polymorphic marker, respectively. Statistical processing of 
the results was carried out using the OpenEpi statistical software package (ver.9.3). 
Statistical processing of data 
The obtained data during the study were subjected to statistical processing on a Pentium-IV 
personal computer using the Microsoft Office Excel 2010 software package, including the use of 
the built-in statistical processing functions, as well as the STATISTICA 6.0 program. The 
statistical significance of the obtained measurements when comparing the average values was 
determined by the Student criterion (t) with the calculation of the probability of error (P) when 
checking the normality of the distribution (by the excess criterion) and the equality of the general 
variances (Fisher's F-test). For statistically significant changes, the confidence level was p <0.05. 
All patients were in hospital for in-patients and they were received pathogenetic and 
symptomatic treatment of coronary artery disease.  
 
RESULTS 
Now existence of the genetic predisposition to development of clottages caused by 
mutations and polymorphic options of the genes coding synthesis of participating proteins of 
haemostatic reactions is proved. Several tens of genetic options associated with disturbances in 
system of a hemostasis and risk of a clottage are taped. A polymorphism of an inhibitor of the 
activator of a plasminogen of the I type (PAI-I), a mutation of a factor of II – a prothrombin, 
factor V Leiden, and also MTHFR gene polymorphisms belong to number of the most important 
of them contributing to development of venous clottages.  
In this regard, we for the first time studied the frequency of occurrence of different options 
of genotypes of a gene of PAI-1, clarification of its role in association with the main RF of IHD. 
Selection criteria for determination of additional prognostic criterion were patients with SA of  
Uzbek nationality.  
The following data on the frequency of occurrence of alleles and genotypes of G5/G4 
polymorphism of a gene of PAI in group of patients with SA and probands specified in tables 1-
1.1 were obtained. 
Тable 1 
Frequency of distribution of alleles of G5/G4 polymorphism of PAI gene in group of 
patients with IHD and healthy individuals 
 
№ 
Groups 
N Frequency alleles 
5G  4G 
N % N % 
1 Main Group 
(n=61) 
61 67 54,9 55 45,1 
2 Control Group (n=65) 65 93 71,5 37 28,5 
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Frequency of alleles of PAI-1 gene is investigated also in the control group consisting of 65 
people (130 chromosomes). Frequency of 4G allele at healthy faces made 37(28,5) %. It is 
revealed 6 (9,2%) homozygous carrier and 25 (38,5%) heterozygous carriers of the given allele. 
Frequency of 5G allele at probands of this group made 93(71,5%). In a homozygous state it was 
revealed at 34 (52,3%) the person. 
Population distribution of alleles of PAI-1 gene is investigated at 61 patients with IHD (122 
chromosomes). Frequency of 4G allele in this group made 55(45,1%). 13 homozygous carriers 
and  29 heterozygous carriers of this allele are revealed. Frequency 5G allele at patients of the 
main group made 67(54,9%). This allele in a homozygous state was revealed at 34 people.  
Table 1.1 
Frequency of distribution of genotypes of G5/G4 polymorphism of PAI gene in group of 
patients with IHD and healthy individuals 
Polymorphism Patients with 
IHD (n=61) 
Healthy individuals with 
risk factors of IHD 
(n=65) 
OR P 
Genotypes 
 4G/4G 
4G/5G 
5G/5G 
  
 13 (21,3%) 
29 (47,5%) 
19(31,1%). 
  
 6 (9,2%) 
25 (38,5%) 
34 (52,3%) 
 
2,66 
1,45 
0,41 
  
  
р<0.05  
 
The analysis of genotyping of the studied persons of the Uzbek nationality showed that, 
at IHD patients mutagen of 4G allele of gene PAI-1 in a homozygous and heterozygous state 
what makes 21,3% and 47,5%, respectively, meets more than in group of healthy faces at which 
given distributions of genotypes made 9,2% and 38,5%. Points these data probability of 
influence of existence of 4G allele of PAI-1 gene, especially in a heterozygous state, to 
development of IHD, in particular of CVD. 
5G/5G the group of healthy faces in number of 34 people in 52.3% of cases, than at 19 
(31,1%) IHD patients caused a stir in the greatest occurrence of a favorable genotype. Thus, 
these differences have the high statistical importance and wear, nonrandom character (р<0.05). 
 
Table 2. 
Distribution of frequencies of genotypes under Hardy-Weinberg's law. The expected and 
observed frequencies of distribution of genotypes on DHW in the main and control groups: 
 Notes:  χ2 =AMOUNT (observed - expected) 2/ expected = ((19-25,66)2/25,66)+((29-
26,14)2/26,14)+((13-9,2)2/9,2)+((34-27,34)2/27,34)+((25-27,86)2/27,86)+((6-9,8)2/9,8)=7,00 
Degree of freedom (df) = (number of columns-1)*( Number of lines-1)=(3-1)*(2-1)=2 
Our indicator is in area р<0.05, calculated with the help of Microsoft Excel p=0.03 
№ 
Groups 
Frequencies of distribution of 
genotypes 
Total χ2 P 
5G/5G G5/G4 4G/4G 
1 
Main Group (n=61) 19 29 13 
n=61 
7,0
0 
0.03 
 Expected frequency (n=61) 25.66 26.14 9.2 
2 Control Group (n=65) 34 25 6 
n=65  Expected frequency (n=65) 27.34 27.86 9.8 
 Total 53 54 19 n=126 
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For this polymorphism at patients with SA and conditionally healthy donors, observed 
distribution of genotypes of this polymorphism correspond to theoretical and has rather high hobs 
and hexp level (the observed and expected heterozygosis) at Hardy-Weinberg's equilibrium 
(р<0.05) on the basis of the Chi-square indicator (χ2=7,00) it is established statistically 
significant differences on distribution of genotypes 5G/5G, G5/G4, 4G/4G between patients of 
the main group and probands of control group (р<0.05). 
Distribution of frequencies of genotypes of a polymorphic marker 4G (-675)5G of PAI-1 
gene in groups of IHD patients depending on a functional class of SA are presented in table 3. 
Table 3 
Distribution of frequencies of genotypes of a polymorphic marker 4G(-75)5G of PAI-1 gene 
in subgroups of IHD patients. 
 
Groups GenePAI-1,detected genotypes, n 
(%) 
Total χ2 P 
 5G/5G 5G/4G 4G/4G  
Patients with SA FC II 6 14 4 
n=24 
1,85 0.39 
Expected  7.48 11.41 5.11 
Patients with SA FC III 13 15 9 
n=37 
Expected  11.52 17.59 7.89 
Total 19 29 13 n=61 
 
Notes: χ2 =AMOUNT (observed - expected)2/observed = 1,85 
Degree of freedom (df)= (Number of columns-1)*(Number of lines-1)=(3-1)*(2-1)=2 
On the р<0.05 significance level, with 2nd degree of freedom, the number in the table must be 
equal to 5,99.  But we have 1,85.  
Our indicatorрis in the areaр>0.05, calculated in calculations with the help of Microsoft Excel 
p=0.39 
Assessment of occurrence of various genotypes of a polymorphic marker 4G(-675)5G of 
PAI-1 gene, established that differences between distribution 5G/5G,5G/4G,4G/4G of genotypes 
depending on FC of SA weren't reliable as HI – a square on persen turned out χ2=1,85 that 
corresponds (р>0.05). On the basis of these results it is possible to assume that, existence of 
heterozygous and homozygous mutagen genotypes of a gene of PAI-1 doesn't influence disease 
severity in a particular on degree of FC of SA. 
When genotyping of the studied groups in relation to the frequency of occurrence of a 
favorable homozygous genotype 5G/5G of PAI gene, in group of patients of CHD, the low 
frequency of this genotype in 31,1% cases, in comparison to statistically significant frequent 
occurrence of a genotype 5G/5G in 52,3% cases among healthy faces is taped. Occurrence at 
patients of SA of a heterozygous polymorphic genotype 5G/4G of PAI gene, made statistically 
significantly 47,5% of cases, in comparison with control group in 38,5% cases (р<0.05) that 
demonstrates probability of high prevalence of this genotype at persons of the Uzbek nationality.  
The frequency distribution of genotypes corresponded to Hardy-Weinberg equilibrium. In 
this regard, was made a comparison of the main clinical parameters and risk factors for 
atherosclerosis in patients with different genotypes of the polymorphic marker 4G (-675) 5G of 
the PAI-1 gene in the group of patients with coronary artery disease. 
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 Table 4 
The vain clinical characteristics of patients with different genotypes of the 
polymorphic marker 4G (-675) 5G of the   PAI-1 gene 
Parameters   Genotype 4G/4G 
(n=13) 
Genotype 4G/5G 
(n=29) 
Genotype 5G/5G 
(n=19) 
P 
Age 59,4±2,46 56,7±1,50 57,6±3,01 р> 0.05 
Hereditary 
history, n(%) 
8(61,5) 19(65,5) 11(57,8) р> 0.05 
АH, n(%) 11(84,6) 27(93,1) 15(78,9) р> 0.05 
BMI>25 
кг/м2, n(%) 
12(92,3) 26(89,6) 14(73,6) р<0.05* 
HCh, n(%) 11(84,6) 18(62,1) 9 (47,4) р<0.05* 
ADS, n(%) 12 (92,3) 28 (96,5) 14 (73,6) р> 0.05 
Hypodynamia, n 
(%) 
9 (69,2) 17 (58,6) 11 (57,9) р<0.05* 
Smoking, n(%) 8(61,5) 9(31,0) 5(26,3) р<0.05* 
     
Note: * - P <0.05 significant difference between the indicators. 
The analysis of interrelation of not modified and modified risk factors with 5G/5G, 
4G/5G and 4G/4G genotypes of PAI-1 gene established that genotyping between groups 
considerably didn't differ depending on age whereas heriditary burdeness on IHD met at a 
heterozygous polymorphic genotype (61,5%) more often, and also a homozygous mutagen 
genotype (65,5%) of patients with IHD, at healthy faces the frequency of genetic predisposition 
between probands with various genotypes appeared almost equally. Among patients of the main 
group with genotypes 4G/4G an obesity of various degree is taped in 46,2% of cases, at a 
genotype of 4G/5G in 37,9% and at 5G/5G 26,3%, therefore is rather more often at patients with 
SAwith an obesity including the third degree of PAI-1 gene mutation was genotyped.  
Connection of mutagen genotypes with smoking appeared to be one of the most 
significant as among patients with heterozygous genotype smokers in 61,5% of cases, in 
comparison with patients with a polymorphic genotype and a homozygous genotype of wild 
allele 5G made 31% and 26,3% of smokers, respectively prevailed. Existence and degree of 
expression of the accompanying ADS at patients of the main group, prevailed at persons with 
mutagen 4G/4G in 92,4% and a polymorphic 4G/5G genotype in 96,5% of cases, and at patients 
with a genotype 5G/5G ADS in rather smaller degree is revealed at 73,6% of cases. HCH was 
also significant RF interconnected with mutagen genotypes as most high cholesterin was 
registered at patients with SA with PAI-1 gene mutation (84,6%), in comparison with patients 
having a polymorphic gene of PAI-1 (62,1%) and a favorable gene of PAI-1 (47,4%). At patients 
with SA with all options of genotypes significant differences on existence of a hypodynamia and 
degree of physical activity it isn't established. 
For assessment of the interconnected influence of mutagen genotypes of a gene of PAI-1 
in associations with IHD RF such as smoking, the accompanying ADS, obesities, HCH and a 
hypodynamia, and also with genetic predisposition the correlation analysis represented in fig. 1 
was carried out. 
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Fig. 1 Correlation analysis of RF and PAI-1 gene’s genotypes 
 
 
The analysis of correlation communication of a mutagen homozygous genotype showed 
that this mutation of a gene of PAI-1 has strong direct correlation with ADS (r= +0,9), smoking 
(r= +0,8), HCH (r= +0,86) and an obesity (r= +0,7), and also average correlation communication 
with a hypodynamia (r= +0,62) and genetic predisposition (r= +0,62). The polymorphic 
heterozygous genotype of a gene of PAI-1 had strong direct correlation link only with ADS (r= 
+0,95) whereas had an average correlation with a hypodynamia (r= +0,68), genetic 
predisposition (r= +0,67), HCH (r= +0,65), an obesity (r= +0,6) and smoking (r= +0,52). Less 
moderate the favorable homozygous genotype 5G/5G with all FR had correlation 
communication: hypodynamia (r= +0,65), ADS (r= +0,5), genetic predisposition (r= +0,5), HCH 
(r= +0,47), smoking (r= +0,45) and obesity (r= +0,45).  
The research of system parameters of a hemostasis depending on genotyping of a gene of 
PAI-1 was conducted only at patients of the main group. Comparison of key parameters of a 
coagulogram at patients with different genotypes of PAI-1 is presented in table 5. 
 
Table 5 
Key parameters of hemostasis system at patients with various genotypes of a polymorphic 
marker 4g (-675) 5g of PAI-1 gene 
Indicator Genotype 4G/4G 
 (n=13)  
Genotype4G/5G 
 (n=29)  
Genotype G/5G  
(n=19)  
P  
Haemotocrit 48.6±10.79  48.3±6.46  48.2±7.20  р> 0.05  
Trombin time 24.3±1.84  23.1±3.90  21.9±11.46  р>0.05  
Fibrinogen 278.4±42.84  248.8±73.94  273.5±77.84  р>0.05  
PI 129.4±2,16  122.2±2.24  108.9±2.15  р<0.05*  
PT 8.5±1.52  9.0±1.74  10.1±5.79  р<0.05*  
aPTT 35.4±20.44  34.1±9.44  34.5±16.74  р>0.05  
INR 0.92±0.11  0.96±0.13  1.11±0.10  р>0.05  
Note:* - Р<0,05 reliable difference of indicators. 
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 Based on the evaluation indicators of coagulogram in patients with SA, revealing 
statistically significant deviation indicators of the external coagulation cascade: the shortening of 
prothrombin time (PT) and the increase of PI, patients with genotype 4G / 4G PT and PI was 8.5 
± 1.52 and 129.4±2.16, in genotype 4G / 5G was 9.0 ± 1.74 and 122.2±2.24, respectively, that 
indicates the likelihood of patient adherence to a hypercoagulable state. 
While in terms of Trombin time, aPTT, fibrinogen, INR has not revealed significant 
differences between the study groups depending on genotyping. 
Thus, the presence of a heterozygous genotype 5G> 4G polymorphic marker PAI-1 gene, 
especially the 4G / 4G mutation in was associated with adherence to hypercoagulability in 
patients with SA, which in turn increases the risk of thrombosis. The results of this study provide 
the basis for the improvement of methods of diagnosis and prognosis of early manifestation of 
coronary heart disease and the development of thromboembolic complications. 
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DISCUSSION 
In this study we define the frequency of the prevalence of RF such as smoking, anxiety 
depressive syndrome, obesity, hypercholesterinemia and hypodynamia, and the presence of 
stress in 63 patients with IHD, in particular SA and 65 healthy individuals in Uzbek nationality, 
based genotyping gene SERPIN1. 
When CAD combined with ADS and psychological distress components, the summation of 
their effect is expected, which may be accompanied by worsening of the clinical course of CAD 
according to the morphological characteristic of platelets, in the direction of enhancing the 
activity of the thrombocyte link of the hemostasis cascade [33]. 
The results of this study showed that the presence and severity of RF such as ADS, obesity 
and hypodynamia authentically prevalent in patients with SA (р<0.05), inparticular in FC III for 
compairing with probands in control group. 
Differences in the frequency of occurrence smokers between the main and control groups 
were not statistically significant, while the degree of nicotine dependence in patients SA was 
significantly higher compared to the level of the NA smokers in healthy subjects (p <0.005). The 
presence of stress was almost the majority of the test, but the main group was dominated by the 
average level of stress, and in the control group most probands revealed lower levels of stress (p 
<0.05). 
Studies have shown that the hereditary risk factors contribute significantly to the 
development of coronary heart disease. Thus, during the decoding of the human genome, 
researchers are paying attention to the molecular genetics of thrombosis and atherosclerosis to 
improve the understanding of the pathophysiology of arterial thrombosis. 
Rangeidentifiedcertaingenesthatcontributetotheriskofdevelopingthedisease.Currently, we proved 
the existence of a genetic predisposition to thrombosis, caused by mutations and polymorphic 
variants of genes coding for the synthesis of proteins participating hemostatic reactions. It 
revealed several dozens of genetic variants associated with disturbances in the hemostatic system 
and the risk of thrombosis. Among the most important of these predisposing to venous 
thrombosis are polymorphism plasminogen activator inhibitor type I (PAI-I), which is widely 
studied makes it possible for the risk of coronary vascular pathologies of venous thrombosis and 
other cardiovascular disorders. 
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It has been shown that level PAI-1 in plasma of blood associated with polymorphism in the 
promoter of the gene PAI-1, which is a single nucleotide deletion / insertion guanine (4G / 5G). 
People who are homozygous for the 4G allele have higher levels of PAI-1 in plasma, and 
homozygous for the 5G allele lower. 
Currently, intensive work on the study of the role and frequency of occurrence mutagenic 
genotypes of genes coagulation balance in the development of arterial thrombosis and ischemic 
heart disease pathogenesis. The data in the literature, a comparative analysis of the frequency 
genotypes risk of MI with levels of the disease in some European countries. 
Due to the relatively frequent of occurrence of mutagenic genotype 4G / 4G of the gene 
PAI-I, we first studied the frequency of occurrence of different variants of genotypes of the gene 
PAI-1, the identification of its role in the development of coronary heart disease in association 
with major RF. 
Population distribution of alleles of the gene PAI-1 was studied in 61 patients with SA. 4G 
allele frequency in this group accounted for 45.1% of cases, while the 5G allele frequency was 
54.9%. allele frequency of PAI-1 was studied as a control group consisting of 65 people. 4G 
allele frequency in healthy individuals accounted for 28.5% of cases, whereas the 5G incidence 
was 71.5%. 
In a stratified analysis by ethnicity [34] noted in their meta-analysis that Asians and 
Caucasians subjects carrying the 4G allele had higher risk of cardiovascular diseases, when Festa 
et al.  reported that the PAI 4G/5G genotype explained 0.63% of the variability of circulating 
PAI-1 levels in non-Hispanic whites, 0.99% in Hispanics, and 2.37% in blacks, and that there 
interaction analyses did not show any statistical differences in the relation between PAI-1 levels 
and the 4G/5G genotype by ethnicity [35]. 
Our study sample was not in HWG equilibrium for the distribution of 4G/5G PAI polymorphism 
among cases and controls (P = 0.003 and P < 0.05 respectively). For that reason, we cannot say 
that the distribution in our sample study describes the real one of this variant among Moroccan 
MI patients. Thus, we cannot conclude about its association with MI risk among Moroccan MI 
patients [36]. 
Analysis of genotyping investigated people of  Uzbek population  showed that, in patients 
with coronary artery disease mutagenic allele 4G of gene PAI-1 in the homozygous and 
heterozygous state, that is 21.3% and 47.5%, respectively, found in more than a group of healthy 
individuals who have a given distribution genotypes was 9.2% and 38.5% .These data indicates 
the likelihood of the presence of the allele 4G of  gene PAI-1, especially in the heterozygous 
state for progression IHD, in particularly SA. 
In addition, studying the relation of these polymorphisms to the level of active PAI-1 in Egyptian 
patients presenting to a single tertiary center in Cairo. On studying the effect of the presence of 
combined mutant genotypes or alleles in CAD patients, STEMI patients showed significantly 
higher frequencies for the presence of combined mutant alleles of PAI-1 4G/5G and PAI-1C/G 
polymorphisms (p 0.016) raising the possibility of multifactorial genetic 
alteration predisposition to acute coronary syndrome [37]. 
Based on the index chi-square (χ2 = 7,00) establishment of statistical significant differences 
in distribution genotypes 5G/5G, 4G/5G, 4G / 4G patients between the main group and the 
control group of probands (p <0.05). When genotyping study groups with respect to the 
frequency of occurrence of favorable homozygous genotype 5G/5G gene PAI-1 in patients with 
SA identified low incidence of this genotype in 31.1% of cases, compared to the frequent of 
occurrence of a statistically significant genotype 5G/5G in 52.3% cases among healthy 
individuals. 
Occurrence in patients with SA heterozygous polymorphic genotype 5G/4G of gene PAI-1 was 
statistically significant 47.5% of cases, compared with the control group, 38.5% in cases (p 
<0.05) that gives evidence high probabilities of genotype prevalence in persons of Uzbekistan 
nationality. When evaluating the frequency of occurrence of mutations of gene PAI-1 fitted that 
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frequency mutagenic homozygous genotype 4G/4G in patients was significantly higher (21.3%) 
compared with the control group (9.2%). 
Also important the fact that the data obtained in the study indicate the importance of early 
detection presence of polymorphic and mutagenic genotypes of gene PAI-1 in the Uzbek 
population.  
In the study, we first studied the incidence of mutagenic genotypes of gene PAI-1 and 
clarify its role in association with major risk factors of IHD in the development of SA. 
Given the multifactorial pathogenesis of coronary artery disease, that is the presence of 
many RF that lead to the development and progression of the disease, were analyzed for the 
presence of the polymorphism associations 4g (-675) 5g gene PAI-1 with clinical and anamnestic 
data, such as smoking, concomitant ADS, obesity, hypercholesterinemia, and physical inactivity 
in the studied groups. 
Based on the findings on the relationship mutagenic genotypes of PAI-1 gene with RF such 
as ADS, smoking, hypercholesterinemia and obesity, as well as considering the relatively 
frequent of occurrence of homozygous 4G / 4G genotype of gene PAI-1 at the Uzbek people, it 
can be assumed about the interconnected influence on the development of IHD mutation of gene 
PAI-1 in combination with dominantly RF. Not enough importance is the fact that, in the course 
of the study detected predictive values polymorphic marker 4G (-675) 5G of gene PAI-1 in 
association with RF: ADS, smoking, obesity and hypercholesterinemia in the development of 
IHD, in particular the SA. 
In order to assess the likely impact of genotypes of polymorphic marker4G (-675) 5G  of 
gene PAI-1  on the flow and the risk of adverse complications of SA, such as blood clot 
organization analyzed the basic parameters of the coagulation balance in patients with SA. 
Discovering new CAD risk factors at the level of genetic regulation of the coagulation and 
fibrinolysis cascades was subjected to intense research investigations. These research studies 
aimed at a better prediction and consequently prevention of this critical condition. Many 
polymorphisms have been implicated in the pathophysiology of CAD [38]. Among these are: 
polymorphisms of PAI-1 at different sites of the gene, which are important in determining PAI-1 
activity thus controlling the balance between coagulation and fibrinolysis [15]. 
Study of the hemostatic system parameters depending on genotyping of gene PAI-1 was 
performed only in patients of the main group. The study detected presence of heterozygous 
genotype 5G>4G polymorphic marker of gene PAI-1, especially the 4G /4G mutation was 
associated with adherence to the hypercoagulability in patients with SA, which in turn increases 
the risk of thrombosis. The results of this study provide the basis for the improvement of 
methods of diagnosis and prognosis of early manifestation of IHD and the development of 
thromboembolic complications.  
The results of this study showed that polymorphism genotype 1.5 times increased risk of 
developing coronary heart disease. Given the relatively frequent of occurrence of polymorphism 
4G (-675) 5G gene PAI-1 in healthy individuals, as well as its association with RF such as 
smoking, obesity, hypercholesterinemia, and ADS, you can expect that in places without timely 
data, other modifications have on the probability distribution function of IHD in particular SA of 
probands in this group. 
In the course of establishing the risk of developing IHD in particular in the presence of SA 
the homozygous 4G/ 4G genotype of gene PAI-1 is increased by more than 2.7 times, indicating 
the importance of the presence detection early mutation gene PAI-1 in population Uzbekistan. 
This indicates that the genotype contributes significantly to the development of the disease and is 
the most informative for determining genetic predisposition to the development of coronary 
artery disease and adverse complications. 
Assessment of the results obtained in this study, can this essential life on the assumption that 
the early development of IHD in healthy people, especially at untimely eliminate the dominant 
risk factors, since the establishment of this correlation relationship mutagenic genotype of gene 
PAI-1 with smoking, obesity, ADS and HCH. This fact must be allow in the optimization 
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methods of early primary and secondary prevention of coronary heart disease in particular in 
fight with the RF. 
 
CONCLUSION 
 The genotyping of the coagulation factor PAI-1 in the examined patients revealed the 
presence of unfavorable genotypes 4G/4G and 4G/5G was established more often in patients 
with coronary artery disease in 21.3% and 47.5% of cases, respectively, compared with the 
group of healthy individuals who This distribution of genotypes was 9.2% and 38.5%. Whereas, 
the prevalence rate of the 5G / 5G genotype was prevalent in 52.3% of the control group over the 
spread of 31.1% of patients in the IHD. 
 In patients with IHD of persons with 4G/5G and 4G/4G genotypes of the PAI-1 gene, there 
was a high incidence in patients with controlled PR: anxiety-depressive syndrome in 96,5% and 
92,4%, obesity in 37,9% and 46,7%, smoking in 61,5% and 31,0%, HCS in 62,1% and 84,6% of 
cases, respectively 
  The presence of the heterozygous genotype 5G> 4G of the polymorphic marker of the 
PAI-1 gene and in particular of the 4G / 4G mutation is associated with a direct predisposition to 
hypercoagulation. In the presence of the 4G / 5G polymorphic genotype, the PAI-1 gene 
increases the risk of developing coronary artery disease by a factor of 1.5, 4G / 4G PAI1 gene 
increases the risk of CHD development and the number of adverse complications by more than 
2.7 times. 
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